Resapp Health Limited (ASX:RAP)
ResApp Health Limited (ASX:RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease.
ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware.
ResApp’s regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea.
Both products are CE Marked in Europe and TGA approved in Australia.